Latest news

• Settlement clears path for Biogen, Samsung’s Humira biosimilar

  Amgen’s agreement was slightly different in that US sales of its Amjevita biosimilar can start from January 31, and both deals include royalty payments to AbbVie, although the details of

• Novartis joins biosimilar Humira push in US

  Pharma giant hopes its candidate will follow in the footsteps of Amgen’s Amjevita and BI’s Cyltezo. ... The biosimilar is vying to be the third copycat version of AbbVie’s Humira (adalimumab) in the big US market after Amgen’s Amjevita and

• AbbVie deal with Amgen sets biosimilar Humira launch dates

  Amgen secured approval in Europe for its biosimilar under the Amgevita brand name in March and in the US as Amjevita a year ago, said that the drug will be one

• Sandoz says Humira biosimilar clears clinical hurdle

  the go-ahead for its product - known as Amjevita in the US market - in September 2016.

• New EU and US approvals for Humira biosimilars

  It is the second to claim marketing approval in the US market after Amgen's Amjevita (adalimumab-atto), which got the go-ahead in September 2016. ... AbbVie is claiming patent protection for Humira in the US out to 2022 and has already taken legal action